肿瘤药品

原研: Tagrisso · AstraZeneca

非小细胞肺癌

原研: Xalkori · Pfizer

ALK 阳性非小细胞肺癌

原研: Alecensa · Roche (Genentech in the US; originated by Chugai Pharmaceutical)

ALK 阳性非小细胞肺癌

原研: Gavreto · Discovered by Blueprint Medicines; co-commercialised with Genentech (Roche) in the US and by Roche ex-US; Blueprint regained global rights (excluding Greater China) in 2023

RET 融合肺癌

原研: Tabrecta · Novartis (discovered by Incyte, licensed to Novartis in 2009)

MET14 跳跃突变肺癌

原研: Lumakras · Amgen

KRAS G12C 突变肺癌

原研: Lorbrena · Pfizer Inc.

ALK 阳性晚期肺癌

原研: Avastin · Genentech, Inc. / F. Hoffmann-La Roche Ltd

多种实体瘤

原研: Herceptin · Genentech, Inc. / F. Hoffmann-La Roche Ltd

HER2 阳性乳腺癌 / 胃癌

原研: Ibrance · Pfizer Inc. (Pfizer Laboratories Div Pfizer Inc)

HR+/HER2- 晚期乳腺癌

原研: Verzenio · Eli Lilly and Company (Lilly USA, LLC)

HR+/HER2- 晚期乳腺癌

原研: Lynparza · AstraZeneca (distributed by AstraZeneca Pharmaceuticals LP); developed and commercialised in collaboration with Merck (MSD outside the US and Canada)

BRCA 突变卵巢癌

原研: Zejula · GlaxoSmithKline (GSK); originally developed by Tesaro (Tesaro UK Limited)

卵巢癌维持治疗

原研: Imbruvica · Pharmacyclics LLC (an AbbVie company) and Janssen Biotech, Inc. (Johnson & Johnson) - developed and commercialised jointly; US distributor of record: Pharmacyclics LLC

淋巴瘤、慢淋白血病

原研: Rituxan · Genentech, Inc. (a member of the Roche Group), with Biogen; Rituxan is jointly marketed by Biogen and Genentech USA in the US; MabThera is marketed by Roche

淋巴瘤、白血病